The DEA recently responded to a petition by Sen. Elizabeth Warren (DMass.) and seven other democratic senators petitioning for the federal government to conduct medical cannabis research (“Response”). The Response was to a series of questions regarding the federal government’s study of cannabis and detailed the DEA interactions with all of the federal agencies involved. Responding to the query as to whether the DEA received the HHS evaluations and scheduling recommendations and a
timeline for a decision, the DEA confirmed that it did receive them and “hopes to release its determination of this petition by the first half of 2016.”
The DEA’s response included cannabis production figures for the National Institute on Drug Abuse's (NIDA) federallysanctioned cannabis grown at the University of Mississippi. Exhibits to the Response showed the cannabis grown largely consists of varying levels of THC-containing
strains and CDB-rich strains. So one might assume if the FDA makes a favorable recommendation on cannabis, then the DEA will reschedule it. Not so fast.
To read the entire article, click here.